207 related articles for article (PubMed ID: 24238093)
1. Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use.
Tsang-A-Sjoe MW; Bultink IE; Voskuyl AE
Clin Exp Rheumatol; 2014; 32(1):95-100. PubMed ID: 24238093
[TBL] [Abstract][Full Text] [Related]
2. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
[TBL] [Abstract][Full Text] [Related]
3. Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark.
Nørgaard JC; Stengaard-Pedersen K; Nørgaard M; de Thurah A
Lupus; 2015 Mar; 24(3):299-306. PubMed ID: 25318969
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
5. Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.
Lee SG; Park EK; Park JH; Kweon SM; Kim YK; Kim GT
Lupus; 2018 Apr; 27(5):753-761. PubMed ID: 29157178
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C; Moroni G
Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
[TBL] [Abstract][Full Text] [Related]
7. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Jorge AM; Melles RB; Zhang Y; Lu N; Rai SK; Young LH; Costenbader KH; Ramsey-Goldman R; Lim SS; Esdaile JM; Clarke AE; Urowitz MB; Askanase A; Aranow C; Petri M; Choi H
Arthritis Res Ther; 2018 Jul; 20(1):133. PubMed ID: 29976231
[TBL] [Abstract][Full Text] [Related]
9. Treatment pathways in an inception lupus cohort over the first three years.
Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus.
Schmajuk G; Yazdany J; Trupin L; Yelin E
Arthritis Care Res (Hoboken); 2010 Mar; 62(3):386-92. PubMed ID: 20391485
[TBL] [Abstract][Full Text] [Related]
11. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial.
Olsen NJ; James JA; Arriens C; Ishimori ML; Wallace DJ; Kamen DL; Chong BF; Liao D; Chinchilli VM; Karp DR
Trials; 2018 Dec; 19(1):694. PubMed ID: 30572906
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
13. Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis.
Xiong WW; Boone JB; Wheless L; Chung CP; Crofford LJ; Barnado A
Lupus; 2019 Jul; 28(8):977-985. PubMed ID: 31189414
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
Durcan L; Clarke WA; Magder LS; Petri M
J Rheumatol; 2015 Nov; 42(11):2092-7. PubMed ID: 26428205
[TBL] [Abstract][Full Text] [Related]
16. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.
Levy RA; Vilela VS; Cataldo MJ; Ramos RC; Duarte JL; Tura BR; Albuquerque EM; Jesús NR
Lupus; 2001; 10(6):401-4. PubMed ID: 11434574
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine: a multifaceted treatment in lupus.
Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
[TBL] [Abstract][Full Text] [Related]
19. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
